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Aims Iron deficiency (ID) is a common co-morbidity in patients with heart failure (HF) and has been suggested to be
associated with poor prognosis. Recently completed double-blind randomised controlled trials (RCTs) studying HF
patients with ID have shown improvements in functional capacity, symptoms and quality of life when treated with i.v.
ferric carboxymaltose (FCM). This individual patient data meta-analysis investigates the effect of FCM vs. placebo on
recurrent hospitalisations and mortality in HF patients with ID.
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Methods
and results
Individual patient data were extracted from four RCTs comparing FCM with placebo in patients with systolic HF
and ID. The main outcome measures were recurrent cardiovascular (CV) hospitalisations and CV mortality. Other
outcomes included cause-specific hospitalisations and death. The main analyses of recurrent events were backed up by
time-to-first-event analyses. In total, 839 patients, of whom 504 were randomised to FCM, were included. Compared
with those taking placebo, patients on FCM had lower rates of recurrent CV hospitalisations and CV mortality [rate
ratio 0.59, 95% confidence interval (CI) 0.40–0.88; P= 0.009]. Treatment with FCM also reduced recurrent HF
hospitalisations and CV mortality (rate ratio 0.53, 95% CI 0.33–0.86; P= 0.011) and recurrent CV hospitalisations
and all-cause mortality (rate ratio 0.60, 95% CI 0.41–0.88; P= 0.009). Time-to-first-event analyses showed similar
findings, with somewhat attenuated treatment effects. The administration of i.v. FCM was not associated with an
increased risk for adverse events.
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Conclusions Treatment with i.v. FCM was associated with a reduction in recurrent CV hospitalisations in systolic HF patients with
ID.
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Introduction
Despite optimal conventional therapy, many patients with heart
failure (HF) remain limited by symptoms, are exercise-intolerant,
and are at high risk for repeated hospitalisations and mortality, all
of which lead to major public health burdens.1,2 Co-morbidities are
common in patients with chronic HF, irrespective of the presence
of preserved or reduced left ventricular ejection fraction (LVEF),
and these may also affect outcomes.3,4
One such co-morbidity is iron deficiency (ID), which is present
in approximately 50% of patients with HF.5–7 Iron plays a central
role in the uptake, transport, storage and metabolism of oxygen,
erythropoiesis and cellular immune response.8,9 The regulation of
systemic iron balance, which is determined by the combination of
dietary iron absorption, utilisation and excretion, is essential to
maintain fundamental cellular functions, particularly in cells that are
characterised by high energy demands, such as skeletal and cardiac
myocytes.8,10–12 At the cellular level, ID is thought to decrease
enzymatic activity of both the Krebs cycle and the respiratory chain
in the mitochondria. As a consequence, ID can lead to disturbance
in the energetic metabolism of cells.13
In HF patients, ID is associated with reduced exercise capac-
ity, impaired quality of life (QoL) and poor prognosis, irrespective
of whether anaemia is present or not.5,14–18 Two recently pub-
lished randomised controlled trials (RCTs) investigating patients
with systolic HF and ID, which compared the effects of i.v. iron as
ferric carboxymaltose (FCM) with placebo, demonstrated impor-
tant improvements in functional capacity, symptoms and QoL.19,20
The clinical and prognostic significance of ID in HF is now well
recognised.7,21,22 However, the available information on the effects
of i.v iron on morbidity and mortality is limited while no such infor-
mation is available for the effects of oral iron on these outcomes.23
The aim of this meta-analysis using individual patient data was
to explore the effect of i.v. FCM relative to placebo on recurrent
hospitalisations and mortality rates, focusing on recurrent cardio-
vascular (CV) hospitalisations. Composite outcomes that consider
only the first event (i.e. time-to-first-event analyses) are subopti-
mal for evaluating the progression of chronic diseases such as HF.
Hospitalisations for worsening HF are an indication of worsening
condition. Taking all such hospitalisations into account is more rep-
resentative of disease progression and more accurately estimates
the effect of treatment on the true burden of disease. It is well
known that an increase in such hospitalisations is associated with
an increased risk for CV mortality. Any censoring attributable to
CV mortality is not independent of the recurrent event process.
Recurrent event analysis investigating this outcome must there-
fore account for the competing risk for CV mortality. Data from
all double-blind RCTs comparing i.v. FCM with placebo in patients
with systolic HF and ID which were closed by 30 June 2016 are
included in this analysis.19,20,24,25
Methods
Study design and inclusion criteria
Four double-blind RCTs investigating the effects of i.v. FCM versus
placebo on clinical outcomes, QoL and symptoms in ambulatory after ..
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.. systolic chronic HF patients with ID that had been closed by 30
June 2016. Data from these four trials, designated FER-CARS-01,
FAIR-HF (NCT00520780),19 EFFICACY-HF (NCT00821717) and
CONFIRM-HF (NCT01453608),20 are included in this meta-analysis.
The main study design features are shown in Table 1. All four studies
were approved by the appropriate regulatory authorities and ethics
committees, and all patients who participated in the individual RCTs
provided written informed consent. The four RCTs were conducted
in strict compliance with the guidelines for Good Clinical Practice
of the International Council for Harmonisation (ICH GCP) and with
the Declaration of Helsinki. The risk for bias from the four RCTs
included in this meta-analysis was limited because the four trials were
randomised, double-blinded, investigated similar patient populations
and used the same iron preparation (i.e. i.v. FCM). A detailed statistical
analysis plan (SAP) was prepared a priori for this meta-analysis. All
four studies included were designed and undertaken by academic
executive committees in conjunction with the sponsor. Authors had
full access to all data and had final responsibility for the decision to
submit for publication.
Outcome measures
For the purpose of this meta-analysis, the main outcome was pre-
defined as the composite of recurrent CV hospitalisations and CV
mortality. Other outcomes included the composites of HF hospitalisa-
tions and CV mortality, CV hospitalisations and all-cause mortality, and
HF hospitalisations and all-cause mortality, in addition to the individ-
ual composite components. All outcomes were assessed in recurrent
event analyses and backed up by time-to-first-event analyses.
Definition of outcomes
For each RCT, reasons for hospitalisations and cause of mortality were
independently adjudicated in a blinded manner by a committee using
predefined criteria detailed in an adjudication charter developed for
that RCT. The same criteria were used across the four RCTs. The
adjudicated outcomes were used in this analysis. All hospitalisations
and deaths were adjudicated irrespective of the investigator’s reported
term. For the purpose of this analysis, all adjudications for ‘worsening
HF’ and ‘other CV’ were combined for the count of ‘any CV hospi-
talisation’. Cause of death was adjudicated as one of the following:
‘(worsening of) HF’; ‘other CV’; ‘non-CV’; ‘serious (study) drug reac-
tion’, and ‘insufficient data to adjudicate’.26 For the purpose of this
analysis, safety outcomes focused on the incidence and frequency of
reported adverse events (AEs).
Statistical analysis
All analyses used individual patient data and are fully documented in a
prespecified SAP. The main outcome analysis was conducted using the
full analysis set (FAS). Event rates (including recurrent hospitalisations)
were analysed using a log-link negative binomial regression model. The
model included fixed covariates of treatment, haemoglobin (Hb) at
baseline, region and random effect for study. Length of observation was
logged and included as an offset variable. Rate ratios, associated 95%
confidence intervals (CIs) and P-values were obtained from the model.
The interaction term between study and treatment was tested on a
separate model to further assess the treatment effect across studies.
Statistical heterogeneity across the studies was quantified using the I2
statistic.
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Design features of the randomised controlled trials included in this meta-analysis
FER-CARS-01 FAIR-HF EFFICACY-HF CONFIRM-HF
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patient population Ambulatory, optimally
treated, systolic CHF with
ID, NYHA class II/III,
eGFR< 60mL/min/1.73m2
Ambulatory, optimally
treated, systolic CHF with
ID, NYHA class II/III
Ambulatory, optimally
treated, systolic CHF with
ID, NYHA class II/III
Ambulatory, optimally
treated, systolic CHF with
ID, NYHA class II/III
Randomisation 2:2:1 (FCM:IS:placebo) 2:1 (FCM:placebo) 1:1 (FCM:placebo) 1:1 (FCM:placebo)
Patients, n (FAS)
FCM/placebo
30/27a/15 304/155 20/14b 150/151
Comparator i.v. FCM vs. IS vs. placeboc i.v. FCM vs. placeboc i.v. FCM vs. placeboc i.v. FCM vs. placeboc
Study duration 12weeks 24weeks 24weeks 52weeks
Calculation of iron
repletion dose
Ganzoni formula using the
mean of two baseline Hb
values
Ganzoni formula using the
mean of two baseline Hb
values
Ganzoni formula using the
mean of two baseline Hb
values
Determined by baseline Hb
values and screening body
weight
Correction phase
duration (i.e. until iron
repletion)
Weekly i.v. injections for
minimally 3, maximally
9weeks
Weekly i.v. injections for
maximally 4weeks
Weekly i.v. injections for
minimally 3, maximally
9weeks
Maximally two i.v. injections
over a 6-week period
Correction phase dosing
regimen (i.e. until iron
repletion)
200mg/100mg iron: FCM or
placebo
200mg/100mg iron: FCM or
placebo
200mg/100mg iron: FCM or
placebo
500mg/1000mg iron: FCM
or placebo
Maintenance phase 4-weekly 200mg iron i.v.
injection (FCM/placebo) up
to 24weeks after
randomisation
4-weekly 200mg iron i.v.
injection (FCM/placebo) up
to 12weeks after
randomisation
4-weekly 200mg iron i.v.
injection (FCM/placebo) up
to 24weeks after
randomisation
3-monthly 500mg iron i.v.
injection (FCM/placebo) up
to 36weeks after
randomisation, if ID still
present
Primary endpoint(s) PGA at week 12 and NYHA
class from baseline to
week 12
PGA at week 24 and NYHA
class from baseline to
week 24
Change in 6MWT and NYHA
class from baseline to
week 24
Change in 6MWT from
baseline to week 24
6MWT, 6-minute walk test; CHF, chronic heart failure; eGFR, estimated glomerular filtration rate; FAS, full analysis set; FCM, ferric carboxymaltose; Hb, haemoglobin; ID, iron
deficiency; IS, iron sucrose; NYHA, New York Heart Association; PGA, patient global assessment.
Ganzoni formula of total iron deficit [mg]: body weight [kg]× (150− actual Hb [g/L])× 0.24+ 500 [mg]. Iron repletion dose, correction of iron deficiency.
aPatients randomised to i.v. IS (n= 27) were not included in this meta-analysis.
bEFFICACY-HF was discontinued as a result of recruitment issues.
cPlacebo, i.v. normal saline.
Time-to-first-event analyses were performed using Cox models
fitted with fixed effects of treatment, Hb at baseline, region and random
study effect. As a sensitivity analysis, a joint frailty model was fitted to
jointly examine hospitalisation and death rates. The model assumed
Poisson and log-logistic distributions for hospitalisation and time to
death, respectively, conditional on the frailty terms, with individual
frailties following a gamma distribution. Rates of HF hospitalisation
followed a negative binomial distribution, and time to CV mortality
followed a Lomax distribution as described by Rogers et al.27
Adverse event incidences were presented as the total number of
events, patients with at least one event and the event rate per 100
patient-years. The joint frailty model analysis was performed using R
Version 3.2.0 (R Foundation for Statistical Computing, Vienna, Austria).
All other analyses were performed using SAS Version 9.3 (SAS Institute,
Inc., Cary, NC, USA).
Results
As of 30 June 2016, four double-blind RCTs comparing FCM with
placebo were closed. In total, 844 patients (507 FCM and 337
placebo) had been randomised in the four RCTs. Data for 839
patients (504 FCM and 335 placebo) were included in this analysis ..
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.. in the FAS, and data for 842 (507 FCM and 335 placebo) were
included in the safety set.
Baseline characteristics
Table 2 shows the baseline characteristics and concomitant medi-
cations for the pooled dataset. The baseline characteristics were
well balanced by treatment allocation, other than New York Heart
Association (NYHA) class, in which, compared with the placebo
pool, a higher proportion of patients allocated to FCM were in
NYHA class III (70% and 61%, respectively, in the FCM and placebo
groups).
Follow-up
The overall mean duration of observation was 31weeks. The
proportion of patients in whom study treatment was stopped pre-
maturely was similar in the two groups (9.5% and 10.7% in the FCM
and placebo groups, respectively). The mean± standard deviation
(SD) FCM dose needed to correct the ID was 1327± 329mg.
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Baseline characteristics
Variable FCM pool
(n= 504)
Placebo pool
(n= 335)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics
Baseline age, years, mean± SD 68.0±10.1 68.3± 10.3
Female, n (%) 246 (49%) 169 (50%)
White European ethnicity, n (%) 502 (100%) 334 (100%)
Clinical features/physical findings
NYHA class, n (%)
II 146 (29%) 128 (38%)
III 354 (70%) 205 (61%)
IV 4 (1%) 2 (1%)
LVEF, mean± SD 33.3± 6.9 34.5± 7.1
BMI, kg/m2, mean± SD 27.9± 4.7 28.3± 5.4
6MWT, distance, m, mean± SD 277±105 284± 106
Cardiovascular risk factors, n (%)
Hypertension 411 (82%) 283 (84%)
Dyslipidaemia 258 (51%) 182 (54%)
Diabetes mellitus 148 (29%) 93 (28%)
Smoking 145 (29%) 92 (27%)
Medical history, n (%)
Atrial fibrillation 179 (36%) 126 (38%)
Myocardial infarction 270 (54%) 183 (55%)
Angina pectoris 300 (60%) 194 (58%)
Stroke 46 (9%) 37 (11%)
Coronary revascularisation 116 (23%) 73 (22%)
Laboratory test results
Hb, g/dL, mean± SD 12.08±1.34 12.20±1.34
Hb <12 g/dL, n (%) 228 (45%) 142 (42%)
Ferritin, ng/mL, mean± SD 54.8± 52.3 59.9± 56.6
Ferritin <100 ng/mL, n (%) 448 (89%) 292 (87%)
TSAT, %, mean± SD 18.5±14.1 17.5± 8.5
TSAT ≤20%, n (%) 338 (67%) 220 (66%)
eGFR (CKD-EPI),
mL/min/1.73m2, mean± SD
62.9± 21.3 63.1± 22.6
eGFR <60mL/min/1.73m2,
n (%)
216 (43%) 156 (47%)
Concomitant treatments, n (%)
Diuretics 465 (92%) 307 (92%)
ACE inhibitor or angiotensin
receptor blocker
473 (93%) 313 (93%)
Beta-blocker 438 (86%) 294 (88%)
Aldosterone antagonists 278 (55%) 174 (52%)
Digitalis glycoside 94 (19%) 80 (24%)
Warfarin 52 (10%) 37 (11%)
Lipid-lowering therapy 272 (54%) 195 (58%)
6MWT, 6-minute walk test; ACE, angiotensin-converting enzyme; BMI, body mass
index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration formula;
eGFR, estimated glomerular filtration rate; FCM, ferric carboxymaltose; Hb,
haemoglobin; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association; SD, standard deviation; TSAT, transferrin saturation.
The overall mean± SD cumulative FCM dose administered was
1679± 522mg.
Outcomes
Table 3 and Figure 1 show the results for recurrent hospitalisations
and mortality. Compared with placebo, FCM significantly reduced
rates of recurrent CV hospitalisations and CV mortality (rate ratio
0.59, 95% CI 0.40–0.88; P= 0.009), recurrent HF hospitalisations
and CV mortality (rate ratio 0.53, 95% CI 0.33–0.86; P= 0.011), ..
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.. recurrent CV hospitalisations and all-cause mortality (rate ratio
0.60, 95% CI 0.41–0.88; P= 0.009), and recurrent HF hospitalisa-
tions and all-cause mortality (rate ratio 0.54, 95% CI 0.34–0.87;
P= 0.011). Figure 2 depicts the extent of the contribution of each
trial to the overall estimate for the main outcome of recurrent CV
hospitalisations and CV mortality.
Table 4 shows the data for the time-to-first-event analyses.
Compared with those in the placebo group, the occurrence of
HF hospitalisations or CV mortality was less frequent in patients
assigned to FCM (hazard ratio 0.55, 95% CI 0.35–0.88; P= 0.012),
as was that of HF hospitalisations or all-cause mortality (hazard
ratio 0.56, 95% CI 0.36–0.88; P= 0.013). Kaplan–Meier plots for
the time-to-first-event analysis are shown in the supplementary
material online (Figure S1).
The median duration for a HF hospitalisation was 10 days (min-
imum: 3 days; maximum: 31 days) for patients randomised to FCM
and 12 days (minimum: 1 day; maximum: 165 days) for patients ran-
domised to placebo.
Prespecified subgroup analysis
Figure 3 depicts the prespecified subgroup analyses performed for
the key subgroups (in tertiles) [Hb, serum ferritin and transferrin
saturation (TSAT)] for the composite outcomes of recurrent CV
hospitalisations and CV mortality, recurrent HF hospitalisations
and CV mortality, and recurrent CV hospitalisations and all-cause
mortality. A substantially lower effect was observed for the three
composite outcomes in the subgroup with TSAT of ≥20.1%.
Safety reporting
The proportion of patients who experienced at least one AE
(serious or non-serious) was similar in both treatment groups,
with incidence rates of 105.4 and 95.8 per 100 patient-years at
risk in the FCM and placebo groups, respectively. The proportions
of patients who withdrew from study treatment as a result of
an AE were 6.3% in patients allocated to FCM and 10.1% in
patients allocated to placebo (Table 5). No serious or severe
hypersensitivity reactions were reported and the nature, type,
intensity and frequency of AEs were similar between the two
treatment groups across the four RCTs.
Sensitivity analysis
A random-effects model analysis was performed and the over-
all rate ratios were consistent with the direction and size of
those calculated by the fixed-effects model. The leave-one-out
cross-validation method was used on the model to investigate the
validity and robustness of the meta-analysis. The results of this val-
idation did not change the overall results.
Discussion
The main finding of the present meta-analysis is that treatment
with i.v. iron (FCM) is associated with lower rates of recurrent
CV hospitalisations and CV mortality in ambulatory, stable, systolic
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Recurrent event outcomes
Outcomes Total events, n (incidence per
100 patient-years of follow-up)
RR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
FCM pool (n= 504) Placebo pool (n= 335)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CV hospitalisations and CV mortality 69 (23.0) 92 (40.9) 0.59 (0.40–0.88) 0.009
HF hospitalisations and CV mortality 39 (13.0) 60 (26.7) 0.53 (0.33–0.86) 0.011
CV hospitalisations and all-cause mortality 71 (23.7) 94 (41.8) 0.60 (0.41–0.88) 0.009
HF hospitalisations and all-cause mortality 41 (13.7) 62 (27.6) 0.54 (0.34–0.87) 0.011
All-cause hospitalisations and all-cause mortality 108 (36.1) 118 (52.5) 0.73 (0.52–1.01) 0.060
HF hospitalisations 22 (7.3) 43 (19.1) 0.41 (0.23–0.73) 0.003
CV hospitalisations 52 (17.4) 75 (33.3) 0.54 (0.36–0.83) 0.004
All-cause hospitalisations 89 (29.7) 99 (44.0) 0.71 (0.50–1.01) 0.056
CI, confidence interval; CV, cardiovascular; FCM, ferric carboxymaltose; HF, heart failure; RR, rate ratio.
A B
C
Rate ratio 0.59 (95% CI: 0.40–0.88), P = 0.009 Rate ratio 0.53 (95% CI: 0.33–0.86), P = 0.011
Rate ratio 0.60 (95% CI: 0.41–0.88), P = 0.009
CV hospitalisation frequency and CV mortality HF hospitalisation frequency and CV mortality
CV hospitalisation frequency and all-cause mortality
Figure 1 Recurrent event analyses for (A) cardiovascular (CV) hospitalisations and CV mortality, (B) heart failure (HF) hospitalisations and
CV mortality, and (C) CV hospitalisations and all-cause mortality. CI, confidence interval; FCM, ferric carboxymaltose.
HF patients with ID. Treatment with i.v. FCM was not associated
with an increased risk for AEs compared with placebo. This is the
first meta-analysis using individual patient data obtained from four
closed RCTs using i.v. iron (FCM) in HF populations with ID.
Recent meta-analyses investigating the effects of treatment with
i.v. iron on hospitalisations and mortality using published data
showed similar benefits of iron treatment with respect to HF
hospitalisations and the combination of HF hospitalisations and
death.28–31 ..
..
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..
..
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..
..
..
. However, the criteria used to determine ID differed between the
RCTs included, as did the i.v. iron therapy and doses used.28–31 Fur-
thermore, the use of erythropoietin-stimulating agents (ESAs) was
allowed in several of these RCTs. Only one of the meta-analyses
analysed recurrent HF hospitalisations.29
In the present meta-analysis, we included individual patient data
from four RCTs that used the same iron preparation (i.v. FCM).
The patient populations included were similar and the same criteria
were used to determine the presence of ID across the four RCTs.
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Favours placeboFavours FCM
(Heterogeneity: Q = 1.5, P = 0.68; I2 = 0%)
Figure 2 Rate ratios for cardiovascular hospitalisations and cardiovascular mortality for the individual randomised controlled trials included
in this meta-analysis. CI, confidence interval; FCM, ferric carboxymaltose.
Table 4 Time-to-first-event outcomes
Outcomes Patients with event, n (incidence per
100 patient-years at risk)
HR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
FCM pool (n= 504) Placebo pool (n= 335)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CV hospitalisation or CV mortality 55 (18.4) 59 (26.2) 0.70 (0.48–1.02) 0.062
HF hospitalisation or CV mortality 32 (10.7) 44 (19.6) 0.55 (0.35–0.88) 0.012
CV hospitalisation or all-cause mortality 57 (19.0) 61 (27.1) 0.70 (0.49–1.02) 0.060
HF hospitalisation or all-cause mortality 34 (11.4) 46 (20.4) 0.56 (0.36–0.88) 0.013
All-cause hospitalisation or all-cause mortality 81 (27.0) 75 (33.3) 0.81 (0.59–1.12) 0.199
HF hospitalisation 19 (6.3) 34 (15.1) 0.42 (0.24–0.74) 0.003
CV hospitalisation 43 (14.4) 52 (23.1) 0.61 (0.40–0.91) 0.017
All-cause hospitalisation 68 (22.7) 67 (29.8) 0.75 (0.53–1.06) 0.099
CV mortality 17 (5.7) 17 (7.6) 0.84 (0.43–1.66) 0.620
All-cause mortality 19 (6.3) 19 (8.4) 0.84 (0.44–1.61) 0.604
CI, confidence interval; CV, cardiovascular; FCM, ferric carboxymaltose; HF, heart failure; HR, hazard ratio.
This allowed for a more accurate, granular and robust assessment
of the relative effects of the administration of i.v. iron (i.e. FCM) on
recurrent hospitalisations and mortality compared with the other
recently performed meta-analyses.28–31
Although ID is recognised as a common and important
co-morbidity in HF, neither screening for ID nor its subse-
quent treatment are yet part of the routine standard of care in this
patient population. There is therefore a need to increase aware-
ness among general practitioners and cardiologists to both identify
and subsequently initiate treatment with i.v. iron (FCM), which
has been shown to have a positive impact on clinical outcome,
physical performance and QoL in this patient population.19–21
This is reflected in the recently updated European Society of Car-
diology (ESC) HF Guidelines 2016, which recommend screening ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
. for ID in HF patients (recommendation IC) and, in addition, to
consider using i.v. FCM in symptomatic systolic HF patients with
ID (recommendation IIaA).21
There is limited evidence of clinically meaningful benefits using
oral iron preparations to treat ID in HF patients. Oral iron is
both poorly absorbed and badly tolerated because of adverse gas-
trointestinal effects, particularly in patients with chronic diseases,
such as HF.32 There are also limited data concerning the efficacy
and safety of other i.v. iron preparations in the treatment of ID
in HF patients. Only three small controlled studies have inves-
tigated the efficacy and safety of i.v. iron sucrose in systolic HF
patients with ID.33–35 The iron sucrose trials enrolled 23, 11 and
20 patients, respectively, and the results showed initial benefits in
improving symptoms, QoL and functional capacity. A larger RCT
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Figure 3 Subgroup analyses for (A) recurrent cardiovascular hospitalisations and cardiovascular mortality, (B) recurrent heart failure
hospitalisations and cardiovascular mortality, and (C) recurrent cardiovascular hospitalisations and all-cause mortality. CI, confidence interval;
FCM, ferric carboxymaltose; TSAT, transferrin saturation.
Table 5 Investigator-reported adverse events
Safety reporting FCM pool (n= 507) Placebo pool (n= 335)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients
with event,
n (%)
Incidence/100
patient-years
at risk
Patients with
event,
n (%)
Incidence/100
patient-years
at risk
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
AEs 317 (62.5%) 105.4 215 (64.2%) 95.8
Serious AEs 86 (17.0%) 28.6 79 (23.6%) 35.2
AEs leading to study drug withdrawal 32 (6.3%) 10.6 34 (10.1%) 15.1
Study drug-related AEs 50 (9.9%) 16.6 20 (6.0%) 8.9
Serious drug-related AEs 0 0 1 (0.3%) 0.4
Study drug-related AEs leading to study drug withdrawal 7 (1.4%) 2.3 3 (0.9%) 1.3
AE, adverse event; FCM, ferric carboxymaltose.
[Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure
(IRONOUT)] recently reported that oral iron did not replenish
depleted iron stores and, as a consequence, did not improve peak
VO2 or any clinically relevant outcomes in HF with reduced ejec-
tion fraction (HFrEF) patients with ID.36 The authors concluded
that the IRONOUT results do not support the use of oral iron
supplementation in HFrEF patients with ID.36
The current treatment recommendations for HF include the
prescription of beta-blockers, ACE inhibitors and/or angiotensin ..
..
..
..
..
..
..
..
..
..
..
..
.. receptor blockers, and diuretics. These treatments play a critical
role in the management of HF. Just over 90% of patients included
in the four RCTs analysed in this meta-analysis were prescribed
at least one of these drugs and could thus be considered as
being ‘optimally treated’. However, despite the optimisation of HF
treatments in systolic HF, post-discharge mortality and readmission
rates for HF in patients with HF remain unacceptably high. This
confirms that other HF co-morbidities should be considered in the
process of defining overall treatment strategies for HF patients.21
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In the exploratory pre-planned subgroup analysis, the reductions
in recurrent CV hospitalisations and CV mortality, in recurrent HF
hospitalisations and CV mortality, and in recurrent CV hospitalisa-
tions and all-cause mortality in the FCM vs. placebo groups were
larger in patients with TSAT in the two lower tertiles (i.e. TSAT
of <12.7% and TSAT of 12.7–20.1%). Although these findings
should be interpreted with caution, they do warrant the targeting
of further research to better understand the role of TSAT in the
definition of ID. Such research is currently ongoing.
The FAIR-HF19 and CONFIRM-HF20 trials contributed approx-
imately 90% of the total number of patients included in our
meta-analysis. A sensitivity analysis was performed and showed that
the overall rate ratios were consistent with the direction and size
of those calculated by the fixed-effects model. The results of our
meta-analysis are limited by sample size, number of deaths and
follow-up duration in the clinical trials included in this analysis,
in addition to the relatively small number of outcomes observed
in the control group. We also recogonise that subgroup analyses
in meta-analyses pose methodological challenges and should be
viewed with caution.
Meta-analyses may provide useful information concerning
treatment-related outcomes and may guide future research. How-
ever, prospective RCTs remain the gold standard method and are
considered to provide the strongest and most robust evidence con-
cerning an intervention. Four large (>1000 patients in each trial)
RCTs evaluating the effects of i.v. iron on mortality and hospitalisa-
tions in differing HF populations are being set up or are currently
recruiting. In three of these RCTs [FAIR-HF2 (NCT03036462),
AFFIRM-AHF (NCT02937454), HEART-FID (NCT03037931)],
patients will be randomised to either i.v. FCM or placebo, and in
the fourth RCT [IRONMAN (NCT02642562)] patients will be
randomised to either i.v. iron isomaltoside or placebo. The results
of all these trials are expected within the next 5 years.
Conclusions
The results of this individual patient data meta-analysis show that
treatment of ID with i.v. FCM in ambulatory systolic HF patients
with ID may decrease recurrent CV hospitalisations. These findings
suggest that i.v. iron therapy may potentially represent a beneficial
addition to the standard medical management of HF. An adequately
powered RCT is needed to confirm these findings.
Supplementary Information
Additional Supporting Information may be found in the online
version of this article:
FigureS1. Kaplan–Meier plots for time-to-first-event analyses.
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